Page 8 - 2014 NECHA E-Brochure

NECHA Annual Meeting:
Making Waves in College Health
October 29-31 ~ Wentworth by the Sea
2014 agenda
Pre-4: Next Level Social Marketing: Applying the 4 Ps
Abstract: Dive deeper into Social Marketing strategy by exploring the “Four Ps”: Product, Price, Place, and Promotion. In this next-level workshop, practice applying these Social Marketing strategies to your own work.
Leah Berkenwald, MA
Coordinator, Wellness Education Wentworth Institute of Technology Timothy Edgar, PhD
Associate Professor Emerson College
CNE (Nursing): 3; CHES: 3; NASW: 1.5
Keynote ~ Keynote ~ Keynote 12:45-1:45pm
Keynote: Discovering Bias: Challenges & Opportunities for Organizational Diversity
Abstract: Many of us believe that we evaluate and treat people fairly. However, despite our best intentions, we often show bias – racial, gender, and otherwise – in our thoughts, feelings, and actions. We will explore the concept of implicit bias, discuss the challenges it presents for leveraging organizational diversity, and consider strategies to mitigate its impact. An informed approach to bias can bring our thoughts, feelings, and actions in line with our organizational – and personal – egalitarian goals.
Keith Maddox, PhD
Associate Professor of Psychology Director, Social Cognition Lab Tufts University
CME: 1; CNE (Nursing): 1; PsyCE: 1; CHES: 1; AAFP: 1; NBCC: 1; NASW: 1
Concurrent Sessions ~ A ~ 2:00-3:30pm
A-1: Pulmonary Embolism, Deep Vein Thrombosis: New Insights in Pathophysiology, Use of 4 Novel Oral
Anticoagulants, and when to Refer for Advanced Therapy beyond Anticoagulation
Abstract: Pulmonary embolism (PE) and deep vein thrombosis (DVT) are no longer considered aggregations of red fibrin clot that can be managed with anticoagulation alone. The root causes include inflammation, classic cardiac risk factors, in addition to hypercoagulability. White blood cells and activated platelets are embedded in the venous thrombus and play an active role in causing clot propagation. Management includes 4 novel anticoagulants, 2 of which are already FDA approved (rivaroxaban and dabigatran) and 2 of which will likely be approved by the date of the 2014 NECHA Annual Meeting. Two of these 4 novel agents require no intravenous or subcutaneous administration, thus potentially leading to less disruption of the lifestyle of the college age population. It is also important to differentiate low-risk venous thromboembolism from potentially high risk PE and DVT. High risk patients may "appear" to be at low risk because of no underlying cardiopulmonary disease. But their clinical condition can deteriorate rapidly. High risk patients need referral to subspecialists for consideration of a thrombolytic therapy, embolectomy, or insertion of a retrievable inferior vena caval filter.
Suffering a PE or DVT is troublesome for anyone, but especially in college health. After all, most patients will superficially appear normal. And they'll have to decline offers of alcohol if they wish to take their anticoagulants properly. And they'll worry about the implications of PE and DVT for their future health and the health of their families. They should become aware of the educational and advocacy activities available to them at the nonprofit North American Thrombosis Forum (www.NATFonline.org).
Samuel Z. Goldhaber, MD
Professor of Medicine, Harvard Medical School Brigham and Women's Hospital, Harvard Medical School CME: 1.5; CNE (Nursing): 1.5; AAFP: 1.5
Program 2 | P a g e